Cargando…

Fatal Acute Liver Failure as a Consequence of Regorafenib Treatment in a Metastatic Colon Cancer

Regorafenib is a multikinase inhibitor which showed benefits in pretreated metastatic colorectal cancer patients. Hepatotoxicity has been described as a frequent side effect. We report the case of a 65-year-old patient presenting with jaundice, fever, and hepatocellular insufficiency which led to de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Béchade, Dominique, Desjardin, Marie, Castain, Claire, Bernard, Pierre-Henri, Fonck, Marianne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618448/ https://www.ncbi.nlm.nih.gov/pubmed/28966584 http://dx.doi.org/10.1159/000479732

Ejemplares similares

Pancreatic Acinar Cell Carcinoma
por: Béchade, Dominique, et al.
Publicado: (2016)

Hepatotoxicities Induced by Neoadjuvant Chemotherapy in Colorectal Cancer Liver Metastases: Distinguishing the True From the False
por: Desjardin, Marie, et al.
Publicado: (2019)

Acute liver failure and seizures as a consequence of regorafenib exposure in advanced rectal cancer
por: Raissouni, Soundouss, et al.
Publicado: (2015)

Cytoreductive Surgery of Colorectal Peritoneal Metastases: Outcomes after Complete Cytoreductive Surgery and Systemic Chemotherapy Only
por: Désolneux, Grégoire, et al.
Publicado: (2015)

Radiofrequency ablation of lung metastases of colorectal cancer: could early radiomics analysis of the ablation zone help detect local tumor progression?
por: Crombé, Amandine, et al.
Publicado: (2023)

Complete response of MSI-high metastatic colon cancer following treatment with regorafenib: A case report
por: Baik, Hyungjoo, et al.
Publicado: (2021)

Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
por: Amram, Marie-Laure, et al.
Publicado: (2017)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
por: Melosky, Barbara
Publicado: (2016)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

Complete post-mortem data in a fatal case of COVID-19: clinical, radiological and pathological correlations
por: Ducloyer, Mathilde, et al.
Publicado: (2020)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
por: Ramaswamy, Anant, et al.
Publicado: (2019)

Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer
por: Lim, Yoojoo, et al.
Publicado: (2015)

Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
por: Yoon, Sang Eun, et al.
Publicado: (2018)

Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib
por: Ricci, Vincenzo, et al.
Publicado: (2020)

Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
por: Karasic, Thomas B, et al.
Publicado: (2022)

Evaluation of Factors Predicting the Effectiveness of Regorafenib in the Treatment of Metastatic Colorectal Cancer
por: Ebinç, Senar, et al.
Publicado: (2022)

Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma
por: Takigawa, Hidehiko, et al.
Publicado: (2016)

Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction: A case report
por: Tsuchihashi, Kenji, et al.
Publicado: (2017)

Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management
por: Khan, Gazala, et al.
Publicado: (2014)

Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report
por: KAWASAKI, KENTA, et al.
Publicado: (2016)

Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer
por: Prager, Gerald, et al.
Publicado: (2017)

Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib
por: Arai, Hiroyuki, et al.
Publicado: (2017)

Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study
por: Aljubran, Ali, et al.
Publicado: (2019)

A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer
por: Xue, Wu-Song, et al.
Publicado: (2018)

Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report
por: Yoshino, Kenji, et al.
Publicado: (2017)

The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer
por: Yoon, Sang Eun, et al.
Publicado: (2019)

Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study
por: Xu, Donghao, et al.
Publicado: (2022)

Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer
por: Lee, Dae-Won, et al.
Publicado: (2023)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction: A case report: Erratum
Publicado: (2017)

FOLFIRI(®) and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms
por: Bécouarn, Yves, et al.
Publicado: (2014)

Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report
por: Tang, Ronald, et al.
Publicado: (2015)

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients
por: Giampieri, Riccardo, et al.
Publicado: (2016)

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice
por: Nannini, Margherita, et al.
Publicado: (2017)

Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer
por: Belli, Valentina, et al.
Publicado: (2017)

Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice
por: Calcagno, Fabien, et al.
Publicado: (2016)

Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients
por: Novakova-Jiresova, Alena, et al.
Publicado: (2020)

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
por: Huemer, Florian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2apign0lpra2qiurmtbjhi9l9p